TEPMETKO 225 mg film-coated tablets
Sponsors
Oslo University Hospital HF, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, HUS-Yhtymae, Intergroupe Francophone De Cancerologie Thoracique, Universita' Degli Studi Di Torino
Conditions
Advanced CancerAdvanced MET exon 14 Mutated Non-Small Cell Lung CancerAdvanced solid tumorCancerMultiple myelomaNon Small Cell Lung CancerNon-Hodgkin lymphomaT-cell prolymphocytic leukemia
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
Improving public cancer care by implementing precision medicine in Norway
A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway
RecruitingCTIS2023-507894-16-00
Start: 2021-04-01Target: 6000Updated: 2026-01-22
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
Not yet recruitingCTIS2024-517478-68-01
Target: 250Updated: 2024-11-06
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:”
“A multi-arms prospective, randomized phase II study to evaluate the best sequential
therapeutic strategis in patients with metastatic non-small cell lung cancer harboring
targetable genomic driver alterations”
Not yet recruitingCTIS2026-525268-16-00
Target: 962Updated: 2026-10-19